SCHEMBL30733922

SCHEMBL30733922

Cc1cccc(C(=O)c2cccc3cccn23)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.46
PARP1 P09874 1/20 0.46
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
FNTA P49354 1/20 0.43
FNTB P49356 1/20 0.43
HPGD P15428 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
KCNK3 O14649 1/20 0.41
KCNH2 Q12809 1/20 0.41
KCNK9 Q9NPC2 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CNR2 P34972 1/20 0.40
MAPT P10636 1/20 0.40
ENPP3 O14638 1/20 0.40
ALPL P05186 1/20 0.40
XIAP P98170 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30733965 0.81 PARP1 (0.46) POLBPARP1FNTAFNTBHPGD
SCHEMBL30733928 0.81 PARP1 (0.46) PARP1FNTAFNTBSMN1; SMN2MEN1
SCHEMBL30733925 0.81 POLB (0.57) POLBPARP1HDAC6SMN1; SMN2MEN1
SCHEMBL29822626 0.79 NPC1 (0.44) POLBSMN1; SMN2TDP1NPC1RAB9A
SCHEMBL27004450 0.79 NPC1 (0.44) POLBSMN1; SMN2TDP1NPC1RAB9A
SCHEMBL27001667 0.78 FFAR1 (0.43) POLBFNTAFNTBMEN1KMT2A
SCHEMBL186545 0.75 PARP1 (0.68) POLBPARP1HDAC8HDAC6HPGD
SCHEMBL29503529 0.75 PARP1 (0.68) POLBPARP1HDAC8HDAC6HPGD
SCHEMBL30733931 0.74 MEN1 (0.41) POLBHPGDMEN1KMT2AMAPT
SCHEMBL6799716 0.74 PBRM1 (0.56) POLBFNTAFNTBSMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228487-A1 FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND APPLICATION THEREOF ZHEJIANG UNIVERSITY (CN) 2024-07-11 US disclosed
EP-4306522-A1 FUSED RING HETEROCYCLIC COMPOUND AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOF Zhejiang University (CN) 2024-01-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228487-A1 FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND APPLICATION THEREOF TRPM2, TRPM8, TRPM7 POLB 4645/4885PARP1 4355/4885HDAC8 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.